Chromadex Corp - CDXC STOCK NEWS

ChromaDex (NASDAQ:CDXC) announced that its Niagen® ingredient has won the NutraIngredients EU Healthy Ageing Ingredient of the Year Award. Niagen, a patented nicotinamide riboside (NR) and the active ingredient in Tru Niagen®, was recognized for its high-quality research and significant contributions to healthy aging. The award highlights Niagen’s impact on cellular health and its potential to support longevity across various generations. ChromaDex's CEO, Rob Fried, expressed honor in receiving the award, emphasizing their mission to tackle aging through NAD+ augmentation. Niagen is backed by extensive research, including studies from two Nobel Prize winners and over 300 published scientific papers.

ChromaDex (NASDAQ:CDXC) reported first quarter 2024 financial results with total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million, and positive Adjusted EBITDA of $0.7 million. The company reiterated a full-year outlook with net sales growth of at least 16%. Tru Niagen® contributed $17.4 million to total net sales, and ChromaDex expanded distribution through partnerships with The Vitamin Shoppe and Sprouts Farmers Market. Operating expenses decreased, net loss improved, and Adjusted EBITDA turned positive. The company aims for revenue growth, gross margin improvement, and increased investments in research and development, marketing, and product launches.

ChromaDex announces an ingredient partnership with Solgar, a Nestlé Health Science brand, introducing Solgar Cellular Energy supplement featuring ChromaDex's NIAGEN NR. The collaboration aims to boost NAD+ levels for cellular health, highlighting NIAGEN as the gold standard in NAD+ supplements. NIAGEN NR, supported by extensive research, increases NAD+ by over 50% in two weeks. Solgar Cellular Energy also includes B vitamins and vitamin C for comprehensive health benefits.

ChromaDex announces the nationwide launch of Tru Niagen® at The Vitamin Shoppe®, making the NAD+ supplement available at 700 retail locations and online. Tru Niagen features NIAGEN®, the most efficient NAD+ precursor, supported by Nobel Prize winners and extensive clinical studies, emphasizing cellular health, recovery, and vitality.

ChromaDex Corp. (NASDAQ:CDXC) will report its first quarter 2024 financial results on May 8, 2024. The company specializes in NAD+ and healthy aging research. An investor conference call will be held to discuss the results and provide a business update. The call will take place at 4:30 p.m. ET on May 8, 2024.

ChromaDex Corp. (NASDAQ:CDXC) announces the major grocery debut of Tru Niagen® at Sprouts Farmers Market, expanding its reach to health-conscious consumers in over 400 locations across 23 states. Tru Niagen®, the top NAD+ supplement for healthy aging in the US, is now available at Sprouts, showcasing ChromaDex's commitment to enhancing access to its products. The partnership with Sprouts aligns with ChromaDex's goal of transforming the aging process for a broader audience.

ChromaDex Corp. announces that its Tru Niagen product line is now third-party verified through the Alkemist Assured program, ensuring quality and transparency in the dietary supplement industry. The company's commitment to excellence and consumer trust is reinforced by this partnership, setting a new industry standard for product verification.

ChromaDex Corp. (NASDAQ:CDXC) reported strong financial results for the fourth quarter and full year 2023, with net sales of $21.2 million and $83.6 million, respectively. The company achieved positive net income, gross margin improvements, and positive adjusted EBITDA. Key highlights include the launch of Tru Niagen® Pro 1,000 mg and successful clinical trials showcasing the benefits of Niagen® in various health conditions.

ChromaDex Corp. (CDXC) schedules a conference call to discuss fourth-quarter 2023 financial results and business update.